Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2007
05/10/2007WO2007053352A2 Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
05/10/2007WO2007053346A1 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
05/10/2007WO2007053145A1 Haloperidol analogs
05/10/2007WO2007053095A1 Chroman compounds as 5-ht1b antagonists
05/10/2007WO2007053094A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS
05/10/2007WO2007053093A1 Chroman compounds as 5 ht1b antagonists
05/10/2007WO2007052999A1 Pharmaceutical compositions combining analgesics and anticonvulsant agents for the treatment of chronic and acute pain
05/10/2007WO2007052124A1 Tetrahydronaphthyridine derivative
05/10/2007WO2007052123A2 Pyrazine derivatives as sodium channel modulators for the treatment of pain
05/10/2007WO2007052013A1 A combination of cannabinoids for the treatment of peripheral neurophatic pain
05/10/2007WO2007051836A2 Compositions for treating dermatological and neurological disorders
05/10/2007WO2007051579A1 Compositions improving brain functions
05/10/2007WO2007051333A1 Triazine beta-secretase inhibitors
05/10/2007WO2007025991A3 Treatment of optic neuritis
05/10/2007WO2007025286A3 Therapy procedure for drug delivery for trigeminal pain
05/10/2007WO2007023479A3 Treatment of central nervous system injury
05/10/2007WO2007022934A3 Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
05/10/2007WO2007020286A3 Method of using potassium channel inhibiting compounds
05/10/2007WO2007007133A3 Composition for treatment of psychosis
05/10/2007WO2006130775A3 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
05/10/2007WO2006125810A3 Composition for slowing down the development of alzheimer's disease
05/10/2007WO2006118959A3 Antibodies directed against amyloid-beta peptide and methods using same
05/10/2007WO2006105313A3 Compositions of and methods of using oversulfated glycosaminoglycans
05/10/2007WO2006069363A3 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
05/10/2007US20070106076 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles
05/10/2007US20070105961 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
05/10/2007US20070105960 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
05/10/2007US20070105958 Compounds for the treatment of metabolic disorders
05/10/2007US20070105956 Drug containing (2r)-2-propyloctanoic acid as the active ingredient
05/10/2007US20070105949 Intermediates for the preparation of lipoxin A4 analogs
05/10/2007US20070105946 Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics
05/10/2007US20070105936 new crystals forms of Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate; VLA-4 (very late antigen-4) inhibitor; therapeutic drug for disorders caused by cell adhesion; water soluble, stability
05/10/2007US20070105933 Amino alcohol compounds
05/10/2007US20070105908 Thiazolimine compound and oxazolimine compound
05/10/2007US20070105901 Novel piperidine derivative
05/10/2007US20070105899 Benzene compounds
05/10/2007US20070105893 e.g. 2-[(4-Ethoxyphenyl)methyl]-1-(3-methylbutyl)-N,N-bis(2,2,2-trifluoroethyl)-1H-benzimidazole-5-carboxamide; agonists at cannabinoid 2 receptor; analgesic agent, anticarcinogenic agent, neurodegenerative diseases; multiple sclerosis, Parkinson's disease, Huntington's chorea or Alzheimer's disease.
05/10/2007US20070105889 Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for therapy of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea
05/10/2007US20070105886 Steroidal compounds for inhibiting steroid sulphatase
05/10/2007US20070105884 Opiate analogs selective for the delta-opioid receptor
05/10/2007US20070105883 Novel physiologically active substances pf127oa, b and c substances
05/10/2007US20070105881 For improving perception, concentration, learning or memory; 2-(Cyclopentylmethyl)-4-[(fluorophenyl)amino]6-oxo-1,6-dihydro-5-pyrimidinecarbonitrile; amination of methyl 2-cyano propenoate derivatives, cyclization using amidinehydrochloride derivatives
05/10/2007US20070105871 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders
05/10/2007US20070105865 Substituted bicyclic quinazolin-4-ylamine derivatives
05/10/2007US20070105860 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors
05/10/2007US20070105859 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors
05/10/2007US20070105845 Quinolone derivatives
05/10/2007US20070105843 Combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
05/10/2007US20070105840 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
05/10/2007US20070105838 Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases
05/10/2007US20070105837 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2][2]-benzazepine, method for the production thereof and use thereof in the production of medicaments
05/10/2007US20070105834 histamine H3 receptor modulators; obesity, diabetes and central nervous system diseases such as vigilance and sleep disorders; e.g. (+)-2-(cyclohexylmethyl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl] -1,2,3 ,4-tetrahydroisoquinoline-7-sulfonamide
05/10/2007US20070105818 Water solubility, bioavailability, oral administration; unit dosage
05/10/2007US20070105191 Capable of inducing chondrocyte proliferation; Chinese Hamster Ovary, an Escheria coli or a yeast host cell with an expression vector
05/10/2007US20070104713 Nogo receptor homologs
05/10/2007DE19681207B4 Therapeutische Verwendung von Rubidiumionen und Zubereitungen Therapeutic Use of rubidium and preparations
05/10/2007DE102005003865A1 Oral composition, useful e.g. to enhance brain function, comprises phosphatidylserine and a flavor compound or its precursor
05/10/2007CA2627779A1 Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
05/10/2007CA2627670A1 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
05/10/2007CA2627423A1 Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors
05/10/2007CA2626435A1 Hypophosphorous acid derivatives and their therapeutical applications
05/10/2007CA2626074A1 A combination of cannabinoids for the treatment of peripheral neurophatic pain
05/10/2007CA2625210A1 Gaba receptor mediated modulation of neurogenesis
05/10/2007CA2624625A1 Tetrahydronaphthyridine derivative
05/10/2007CA2610480A1 Nanoparticulate acetaminophen formulations
05/09/2007EP1783227A1 Humanized anti-CCR2 antibodies and methods of use therefor
05/09/2007EP1783141A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
05/09/2007EP1783120A1 Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles
05/09/2007EP1782837A2 Hapten-carrier conjugates for use in drug-abuse therapy (nicotine)
05/09/2007EP1782836A2 Hapten-carrier conjugates for use in drug-abuse therapy (cocaine)
05/09/2007EP1782835A2 Hapten-carrier conjugates for use in drug-abuse therapy
05/09/2007EP1782821A1 Drug and method for improving brain function
05/09/2007EP1782815A1 Compounds for the treatment of an acute injury to the central nervous system
05/09/2007EP1782813A1 The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
05/09/2007EP1782812A1 Compounds for the treatment of inflammation of the central nervous system
05/09/2007EP1782806A1 Compositions for treating dermatological and neurological disorders
05/09/2007EP1781703A1 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
05/09/2007EP1781686A2 Vla-4 antagonists
05/09/2007EP1781666A1 Improved process for making form i of olanzapine.
05/09/2007EP1781665A2 Olanzapine salts and their conversion to olanzapine free base
05/09/2007EP1781659A2 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
05/09/2007EP1781652A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists
05/09/2007EP1781645A1 Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
05/09/2007EP1781644A1 Macrocyclic beta-secretase inhibitors
05/09/2007EP1781641A1 Pyrrolo-naphthyl acids as pai-1 inhibitors
05/09/2007EP1781631A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
05/09/2007EP1781630A1 Novel piperidine derivative for the treatment of depression
05/09/2007EP1781623A1 Compounds and compositions useful as cathepsin s inhibitors
05/09/2007EP1781619A1 Sigma receptor inhibitors
05/09/2007EP1781618A1 Sigma receptor inhibitors
05/09/2007EP1781614A1 Compounds which potentiate glutamate receptor and uses thereof in medicine
05/09/2007EP1781613A1 Piperidine derivatives as histamine h3 receptor ligands
05/09/2007EP1781612A1 Shortened method for the production of l-lobeline
05/09/2007EP1781602A1 4-sulfonyl-substituted benzoylalanine derivatives useful as kynurenine-aminotransferase inhibitors
05/09/2007EP1781596A1 Amino acid derived prodrugs of propofol compositions and uses thereof
05/09/2007EP1781294A2 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
05/09/2007EP1781292A1 Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one
05/09/2007EP1781291A1 Opioids for the treatment of the restlessness of the lower limbs
05/09/2007EP1781290A2 Anti-inflammatory agents
05/09/2007EP1781288A2 Modulators of muscarinic receptors
1 ... 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 ... 1833